Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Lung Cancer treatment details. Biologic therapy. Chemotherapy. Yale Cancer Center and Smilow Cancer Hospital, New Haven, CT, United States



Survival: 9.7 months
   
Toxicity Grade: 5
   
Treatments: Biologic therapy
Chemotherapy
   
Drugs:
Country: United States
   
City/State/Province: New Haven, CT
   
Hospital: Yale Cancer Center and Smilow Cancer Hospital
   
Journal: Link
   
Date: 4/2012

Description:
Patients:
This phase II study involved non-small cell lung cancer patients who had not been previously treated with chemotherapy and were divided into separate treatment groups. Group A consisted of 66 patients with a median age of 62 years and 74% male. Group B consisted of 70 patients with a median age of 59 years and 76% male.

Treatment:
Patients in group A were treated with the chemotherapy agents paclitaxel and carboplatin.

Patients in group B were treated with paclitaxel and carboplatin in addition to the biologic therapy agent ipilimumab, which is a monoclonal antibody that blocks a protein called CTLA-4 and helps the immune system target cancer cells.

Toxicities:
There was one treatment-related death due to sepsis (infection) reported in group A. Grade 4 thrombocytopenia and neutropenia was also reported.

There was one treatment-related death due to sepsis (infection) reported in group B. Grade 4 fatigue, neutropenia, and anemia were also reported.

Results:
The median overall survival for groups A and B were 8.3 and 9.7 months, respectively.

Support:
This study was supported by Bristol-Myers Squibb, makers of ipilimumab (brand name Yervoy).

Correspondence: Dr. Thomas Lynch; email: thomas.lynch@yale.edu

E-mail to a Friend Email Physician More Information